Published in J Natl Cancer Inst on August 09, 2012
The RCT of Acupuncture on PCOS Combined With IR | NCT02491333
Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ (2016) 2.37
Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol (2014) 1.82
Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care (2014) 1.68
Latest insights into the risk of cancer in diabetes. J Diabetes Investig (2013) 1.01
A Review on the Relationship between SGLT2 Inhibitors and Cancer. Int J Endocrinol (2014) 1.00
Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial. PLoS One (2015) 0.96
Bladder cancer in 2012: Challenging current paradigms. Nat Rev Urol (2013) 0.96
Distinguishing incident and prevalent diabetes in an electronic medical records database. Pharmacoepidemiol Drug Saf (2013) 0.93
Management of type 2 diabetes mellitus in older adults. Diabetes Metab J (2012) 0.92
Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci (2014) 0.91
Obesity-driven inflammation and cancer risk: role of myeloid derived suppressor cells and alternately activated macrophages. Am J Cancer Res (2013) 0.89
Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings. BMC Health Serv Res (2014) 0.89
Optimal therapy of type 2 diabetes: a controversial challenge. Aging (Albany NY) (2014) 0.85
Urinary tuberculosis is associated with the development of urothelial carcinoma but not renal cell carcinoma: a nationwide cohort study in Taiwan. Br J Cancer (2013) 0.85
Diabetes and risk of bladder cancer among postmenopausal women in the Iowa Women's Health Study. Cancer Causes Control (2013) 0.84
The peroxisome-proliferator activated receptor-γ agonist pioglitazone modulates aberrant T cell responses in systemic lupus erythematosus. Clin Immunol (2013) 0.83
Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study. J Korean Med Sci (2014) 0.83
Pseudoginsenoside F11, a Novel Partial PPAR γ Agonist, Promotes Adiponectin Oligomerization and Secretion in 3T3-L1 Adipocytes. PPAR Res (2013) 0.82
Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chronic Dis (2014) 0.82
Pioglitazone: A prudent prescription. Indian J Endocrinol Metab (2013) 0.81
Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study. PLoS One (2013) 0.81
Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol (2015) 0.80
Incidence and Survival of urothelial carcinoma of the urinary bladder in Norway 1981-2014. BMC Cancer (2016) 0.78
Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes. Medicine (Baltimore) (2016) 0.78
Deciphering the Roles of Thiazolidinediones and PPARγ in Bladder Cancer. PPAR Res (2017) 0.75
Incidence and Mortality Risks of Cancer in Patients with Type 2 Diabetes: A Retrospective Study in Shanghai, China. Int J Environ Res Public Health (2016) 0.75
Acupuncture treatment for insulin sensitivity of women with polycystic ovary syndrome and insulin resistance: a study protocol for a randomized controlled trial. Trials (2017) 0.75
Mechanisms of current therapies for diabetes mellitus type 2. Adv Physiol Educ (2012) 0.75
Diabetic oncopathy--one more yet another deadly diabetic complication! Indian J Med Res (2014) 0.75
Letter: the risk of bladder cancer in korean diabetic subjects treated with pioglitazone (diabetes metab j 2012;36:371-8). Diabetes Metab J (2012) 0.75
Association of Itraconazole, a Hedgehog Inhibitor, and Bladder Cancer. J Urol (2016) 0.75
Real world evidence: An Indian perspective. Perspect Clin Res (2016) 0.75
Targets for body fat, blood pressure, lipids, and glucose-lowering interventions in healthy older people. Diabetes Care (2013) 0.75
Generalized enrichment analysis improves the detection of adverse drug events from the biomedical literature. BMC Bioinformatics (2016) 0.75
Seeding of a high-grade papillary urothelial carcinoma of the bladder along a nephroureterostomy tract. Radiol Case Rep (2017) 0.75
Evaluation of methods to estimate missing days' supply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). Eur J Clin Pharmacol (2016) 0.75
Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract (2009) 25.83
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
The Read clinical classification. BMJ (1990) 15.83
The impact of confounder selection criteria on effect estimation. Am J Epidemiol (1989) 13.34
Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol (2003) 11.24
Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol (2010) 10.70
Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics (1998) 8.48
Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract (2010) 7.41
Purposeful selection of variables in logistic regression. Source Code Biol Med (2008) 6.18
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf (2007) 5.93
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA (2007) 5.89
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA (2007) 5.02
Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care (2004) 4.39
Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia (2006) 2.91
Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A (1999) 2.45
Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer (2003) 2.43
Validation of death and suicide recording on the THIN UK primary care database. Pharmacoepidemiol Drug Saf (2009) 2.29
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A (2000) 2.23
Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care (2011) 2.00
Thiazolidinediones and fractures in men and women. Arch Intern Med (2009) 1.98
Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer (2003) 1.86
Cancer incidence in The Health Improvement Network. Pharmacoepidemiol Drug Saf (2009) 1.65
Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf (2009) 1.61
Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia (2011) 1.59
Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther (2006) 1.57
Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol (2001) 1.48
Responding to an FDA warning--geographic variation in the use of rosiglitazone. N Engl J Med (2010) 1.46
Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer (2011) 1.29
Validation of THIN data for non-melanoma skin cancer. Qual Prim Care (2008) 1.24
Diabetes and risk of bladder cancer: evidence from a case-control study in New England. Cancer (2010) 1.21
A meta-analysis on the association between bladder cancer and occupation. Scand J Urol Nephrol Suppl (2008) 1.20
Validation of The Health Improvement Network (THIN) database for epidemiologic studies of chronic kidney disease. Pharmacoepidemiol Drug Saf (2011) 1.11
PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. Cancer Lett (2005) 0.98
Association between diagnosed diabetes and self-reported cancer among U.S. adults: findings from the 2009 Behavioral Risk Factor Surveillance System. Diabetes Care (2011) 0.97
Attenuation of peroxisome proliferator-activated receptor gamma (PPARgamma) mediates gastrin-stimulated colorectal cancer cell proliferation. J Biol Chem (2006) 0.93
Screening for bladder cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2011) 0.92
Race, ethnicity, and use of thiazolidinediones among US adults with diabetes. Curr Med Res Opin (2007) 0.85
Role of computerized physician order entry systems in facilitating medication errors. JAMA (2005) 26.32
Linking long-term dietary patterns with gut microbial enterotypes. Science (2011) 17.30
Creating healthy food and eating environments: policy and environmental approaches. Annu Rev Public Health (2008) 10.04
Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA (2006) 9.53
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf (2007) 5.93
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63
The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients. Clin Infect Dis (2010) 5.34
Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med (2003) 5.09
The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology (2002) 4.98
Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. BMC Microbiol (2010) 4.97
Oral contraceptives and the risk of breast cancer. N Engl J Med (2002) 4.85
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol (2007) 4.45
Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol (2003) 4.27
Physical activity and food environments: solutions to the obesity epidemic. Milbank Q (2009) 4.20
Design of a national distributed health data network. Ann Intern Med (2009) 4.09
Interventions to prevent skin cancer by reducing exposure to ultraviolet radiation: a systematic review. Am J Prev Med (2004) 4.07
Effectiveness of interventions to increase screening for breast, cervical, and colorectal cancers: nine updated systematic reviews for the guide to community preventive services. Am J Prev Med (2012) 4.07
The effectiveness of worksite nutrition and physical activity interventions for controlling employee overweight and obesity: a systematic review. Am J Prev Med (2009) 3.84
The role of built environments in physical activity, eating, and obesity in childhood. Future Child (2006) 3.66
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology (2004) 3.57
The human gut virome: inter-individual variation and dynamic response to diet. Genome Res (2011) 3.32
Weight gain in the first week of life and overweight in adulthood: a cohort study of European American subjects fed infant formula. Circulation (2005) 3.28
The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf (2005) 3.24
Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ (2013) 3.22
Statin use and the risk of 10 cancers. Epidemiology (2007) 3.17
Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res (2006) 3.06
Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage (2003) 3.05
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol (2002) 3.01
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet (2009) 2.85
The FDA and drug safety: a proposal for sweeping changes. Arch Intern Med (2006) 2.74
Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med (2014) 2.73
Facial emotion recognition in schizophrenia: intensity effects and error pattern. Am J Psychiatry (2003) 2.69
Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS (2006) 2.57
A cognitive neuroscience-based computerized battery for efficient measurement of individual differences: standardization and initial construct validation. J Neurosci Methods (2009) 2.55
Age group and sex differences in performance on a computerized neurocognitive battery in children age 8-21. Neuropsychology (2012) 2.54
Rapid evolution of the human gut virome. Proc Natl Acad Sci U S A (2013) 2.53
Retrospective drug utilization review, prescribing errors, and clinical outcomes. JAMA (2003) 2.51
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA (2012) 2.51
Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ (2002) 2.46
Use of abdominopelvic computed tomography in emergency departments and rates of urgent diagnoses in Crohn's disease. Clin Gastroenterol Hepatol (2011) 2.40
Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am J Gastroenterol (2002) 2.39
Vitamin and mineral use and risk of prostate cancer: the case-control surveillance study. Cancer Causes Control (2008) 2.35
Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma. Am J Surg Pathol (2006) 2.34
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med (2005) 2.34
The effect of electronic self-monitoring on weight loss and dietary intake: a randomized behavioral weight loss trial. Obesity (Silver Spring) (2010) 2.32
The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol (2007) 2.32
Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology (2012) 2.26
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis (2012) 2.23
The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results. Ann Epidemiol (2002) 2.21
Comparison of objective and patient-reported hot flash measures in men with prostate cancer. J Support Oncol (2009) 2.20
Using mHealth technology to enhance self-monitoring for weight loss: a randomized trial. Am J Prev Med (2012) 2.20
Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation (2012) 2.19
Nutrition Environment Measures Study in restaurants (NEMS-R): development and evaluation. Am J Prev Med (2007) 2.19
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol (2010) 2.18
Using wireless handheld computers and tailored text messaging to reduce negative consequences of drinking alcohol. J Stud Alcohol Drugs (2007) 2.18
Managed problem solving for antiretroviral therapy adherence: a randomized trial. JAMA Intern Med (2013) 2.16
Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2006) 2.16
Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology (2005) 2.15
Statin use and the risk of breast and prostate cancer. Epidemiology (2002) 2.15
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 2.15
Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology (2006) 2.14
Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol (2012) 2.14
American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol (2010) 2.14
Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf (2002) 2.12
Differences in facial expressions of four universal emotions. Psychiatry Res (2004) 2.11
Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol (2006) 2.09
White paper on CTSA consortium role in facilitating comparative effectiveness research: September 23, 2009 CTSA consortium strategic goal committee on comparative effectiveness research. Clin Transl Sci (2010) 2.09
AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology (2010) 2.09
An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index. Inflamm Bowel Dis (2014) 2.05
Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics (2012) 2.04
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken) (2015) 2.03
The use of theory in health behavior research from 2000 to 2005: a systematic review. Ann Behav Med (2008) 2.03
Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis (2008) 2.03
Evidence-based approaches to dissemination and diffusion of physical activity interventions. Am J Prev Med (2006) 2.03
Detection of proximal adenomatous polyps with screening sigmoidoscopy: a systematic review and meta-analysis of screening colonoscopy. Arch Intern Med (2003) 2.02
Type I and II endometrial cancers: have they different risk factors? J Clin Oncol (2013) 2.01
Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidemiol Drug Saf (2013) 2.01
SMART trial: A randomized clinical trial of self-monitoring in behavioral weight management-design and baseline findings. Contemp Clin Trials (2009) 2.01
Obesogenic neighborhood environments, child and parent obesity: the Neighborhood Impact on Kids study. Am J Prev Med (2012) 1.99
Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative. J Infect Dis (2006) 1.96
Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology (2003) 1.94
Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. Arthritis Care Res (Hoboken) (2013) 1.92
Risk of kidney injury following oral phosphosoda bowel preparations. J Am Soc Nephrol (2007) 1.89
Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl (2005) 1.87